Clobetasol propionate 0.05% under occlusion for alopecia areata: Clinical effect and influence on intraocular pressure

Nomiyama, Tomoko; Katoh, Norito

doi:10.1111/ajd.13479

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clobetasolpropionat-Schaum wurde als sichere und gut verträgliche Behandlung für die AA mit guter kosmetischer Akzeptanz und Compliance sowie optimaler Wirkung unter Okklusion beschrieben [97]. In einer kürzlich durchgeführten Studie mit 43 Patienten, die 0,05%ige Clobetasolpropionat-Lotion erhielten, wuchsen bei 85 % der Patienten mit umschriebener AA mehr als 80 % der Haare nach, während 57 % der AT-und 80 % der AU-Patienten keine Reaktion zeigten [98]. In einer Studie über die Wirksamkeit von Clobetasolpropionat 0,05 % bei lang anhaltender AT und AU wurden 28,5 % der Patienten erfolgreich behandelt, und nur bei 18 % wuchsen die Haare wieder nach [99].…”

Section: Kortikosteroide Topische Kortikosteroideunclassified

Alopecia areata – Aktuelles Verständnis und Management

Lintzeri

Constantinou

Hillmann

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Die Alopecia areata (AA) ist eine chronische immunvermittelte Erkrankung, die durch akuten oder chronischen, nicht vernarbenden Haarausfall gekennzeichnet ist. Die klinischen Erscheinungsformen sind sehr unterschiedlich und reichen von kleinen umschriebenen haarlosen Stellen bis hin zum vollständigen Verlust der Kopf-und Körperbehaarung. Diese Übersicht soll aktuelles Wissen zu Pathophysiologie und beteiligten Signalwegen vermitteln sowie diagnostische und therapeutische Empfehlungen geben. Aktuell verfügbare Therapieansätze bei AA, einschließlich topischer, systemischer und injizierbarer Interventionen, zeigen unterschiedlich gutes Ansprechen mit häufigen Rezidiven, was den dringenden Bedarf an effektiven zielgerichteten Therapien widerspiegelt. Neue therapeutische Ansätze und Konzepte, einschließlich Januskinase-Inhibitoren, werden mit großer Spannung erwartet. Diese Übersicht diskutiert traditionelle und neue Therapieansätze für das Management der AA. Diese Erkrankung führt häufig zu einer starken psychosozialen Belastung für die Betroffenen, kann zu Depressionen führen, Angstzustände auslösen und die Lebensqualität beeinträchtigen. Daher sollten psychosoziale Aspekte der Krankheit mit berücksichtigt, beim Patienten angesprochen und die Notwendigkeit einer psychologischen Unterstützung erwogen werden.

show abstract

Section: Kortikosteroide Topische Kortikosteroideunclassified

Alopecia areata – Aktuelles Verständnis und Management

Lintzeri

Constantinou

Hillmann

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…treatment for AA, with good cosmetic acceptance and compliance, and optimized effects under occlusion [97]. In a recent study of 43 patients receiving 0.05 % clobetasol propionate lotion, 85 % of patients with patchy AA experienced more than 80 % of hair regrowth, whereas ∼ 57 % of AT, and 80 % of AU patients had no response [98]. In a study on the efficacy of clobetasol propionate 0.05 % in long-lasting AT and AU, 28.5 % of the patients were treated successfully, and only 18 % maintained hair regrowth [99].…”

Section: Corticosteroids Topical Corticosteroidsmentioning

confidence: 99%

Alopecia areata – Current understanding and management

Lintzeri

Constantinou

Hillmann

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Alopecia areata (AA) is a chronic, immune-mediated disease characterized by acute or chronic non-scarring hair loss, with a heterogeneity in clinical manifestations ranging from patchy hair loss to complete scalp and body hair loss. An overview of the up-to-date pathophysiology and the underlying signaling pathways involved in AA together with diagnostic and therapeutic recommendations will be provided. Current treatments, including topical, systemic and injectable interventions show varying response and frequent relapses reflecting the unmet clinical need. Thus, the new emerging concepts and therapeutic approaches, including Janus kinase inhibitors are eagerly awaited. Traditional and emerging therapies of AA will be discussed, in order to provide physicians with guidance for AA management. Since the latter is so challenging and often tends to take a chronic course, it can have an enormous psychosocial burden on patients, compromising their quality of life and often causing depression and anxiety. Therefore, the psychosocial aspects of the disease need to be evaluated and addressed, in order to implement appropriate psychological support when needed.

show abstract

“…The occlusive dressing technique (ODT) enabling higher absorption of topically applied 0.05% clobetasol propionate has been attempted to treat AT/AU (Figure 6). 109,110 In a case series study, 28 patients with AT or AT/AU applied 2.5 g of 0.05% clobetasol propionate ointment to half of the scalp every night under occlusion with a plastic film 109 . Intriguingly, 28.5% of testees demonstrated successful hair regrowth on the treated site and eventually achieved almost complete hair regrowth after extension of the treatment to the whole scalp 109 .…”

Section: Treatmentmentioning

confidence: 99%

Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines

Fukuyama

Ito

Ohyama

2021

The Journal of Dermatology

View full text Add to dashboard Cite

Alopecia areata (AA) is a relatively common nonscarring hairloss disease characterized by an autoimmune response to anagen hair follicles (HFs). Accumulated evidence suggests that collapse of the HF immune privilege subsequent to triggering events, represented by viral infection, leads to autoimmune response in which autoreactive cytotoxic CD8+NKG2D+ T cells mainly target exposed HF autoantigens. AA had been recognized as type 1 inflammatory disease, but recent investigations have suggested some roles of type 2‐ and Th17‐associated mediators in AA pathogenesis. The significance of psychological stress in AA pathogenesis is less emphasized nowadays, but psychological comorbidities, such as depression and anxiety, attract greater interest in AA management. In this regard, the disease severity may not solely be evaluated by the extent of hair loss. Use of trichoscopy markedly improved the resolution of the diagnosis and evaluation of the phase of AA, which is indispensable for the optimization of treatment. For the standardization of AA management, the establishment of guidelines/expert consensus is pivotal. Indeed, the Japanese Dermatological Association (JDA) and other societies and expert groups have published guidelines/expert consensus reports, which mostly recommend intralesional/topical corticosteroid administration and contact immunotherapy as first‐line treatments, depending on the age, disease severity, and activity of AA. The uniqueness of the JDA guidelines can be found in their descriptions of intravenous corticosteroid pulse therapy, antihistamines, and other miscellaneous domestically conducted treatments. Considering the relatively high incidence of spontaneous regression in mild AA and its intractability in severe subsets, the importance of course observation is also noted. Evidenced‐based medicine for AA is currently limited, however, novel therapeutic approaches, represented by JAK inhibitors, are on their way for clinical application. In this review, the latest understanding of the etiopathogenesis and pathophysiology, and update on therapeutic approaches with future perspectives are summarized for AA, following the current version of the JDA AA management guidelines.

show abstract

Clobetasol propionate 0.05% under occlusion for alopecia areata: Clinical effect and influence on intraocular pressure

Cited by 5 publications

References 10 publications

Alopecia areata – Aktuelles Verständnis und Management

Alopecia areata – Aktuelles Verständnis und Management

Alopecia areata – Current understanding and management

Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines

Contact Info

Product

Resources

About